Robert S. Landsman

Array ( [id] => 19916217 [patent_doc_number] => 12291571 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody [patent_app_type] => utility [patent_app_number] => 17/864000 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 4961 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19319592 [patent_doc_number] => 20240241135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => Antibody Combination Against Regenerating Islet-Derived Protein 1a And Detection Kit Comprising Same [patent_app_type] => utility [patent_app_number] => 18/562179 [patent_app_country] => US [patent_app_date] => 2022-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18159140 [patent_doc_number] => 20230025732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/855510 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17855510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18512534 [patent_doc_number] => 20230228738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING G PROTEIN COUPLED RECEPTOR MEDIATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/850169 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18044875 [patent_doc_number] => 11518816 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-06 [patent_title] => Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy [patent_app_type] => utility [patent_app_number] => 17/846738 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 34429 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447187 [patent_doc_number] => 20240307317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => TAILORED HYPOIMMUNENANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORE, HEREDITARY AND INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 18/571007 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18571007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19779550 [patent_doc_number] => 12228580 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Methods of assigning a COVID pathological type based on a cytokine/chemokine panel [patent_app_type] => utility [patent_app_number] => 17/842293 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 18680 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20014466 [patent_doc_number] => 20250152688 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => A Conjugate [patent_app_type] => utility [patent_app_number] => 18/568716 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077408 [patent_doc_number] => 20220403020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => METHODS OF TREATMENT USING ILT7 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/831784 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380983 [patent_doc_number] => 20240270853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTI-DDR2 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/289627 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579888 [patent_doc_number] => 12145986 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta) [patent_app_type] => utility [patent_app_number] => 17/804396 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 25 [patent_no_of_words] => 21547 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17804396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316758 [patent_doc_number] => 20240238298 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy [patent_app_type] => utility [patent_app_number] => 18/561673 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005003 [patent_doc_number] => 20220363769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/752710 [patent_app_country] => US [patent_app_date] => 2022-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851941 [patent_doc_number] => 20220281983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => METHODS FOR PROMOTING T CELLS RESPONSE [patent_app_type] => utility [patent_app_number] => 17/740849 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318326 [patent_doc_number] => 20240239869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => SINGLE CHAIN TRIMER MHC CLASS I NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/289674 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297597 [patent_doc_number] => 20240226163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/559009 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -131 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328280 [patent_doc_number] => 11633497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Anti-c-Met antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 17/661450 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 9033 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17661450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263614 [patent_doc_number] => 20240207311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => TUMOR INFILTRATING LYMPHOCYTES THERAPY [patent_app_type] => utility [patent_app_number] => 18/287334 [patent_app_country] => US [patent_app_date] => 2022-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246920 [patent_doc_number] => 20240197904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => COMBINATION THERAPY FOR TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 18/288108 [patent_app_country] => US [patent_app_date] => 2022-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263615 [patent_doc_number] => 20240207312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS [patent_app_type] => utility [patent_app_number] => 18/287542 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287542 [rel_patent_id] =>[rel_patent_doc_number] =>)